Inhibitor of the replication of herpes simplex viruses 1 and 2 (HSV-1 and HSV-2)

Novel Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor

Cofactor for mitochondrial deacetylase sirtuin-3 enzyme, regulating energy metabolism and immunity and modulating inflammasome assembly

Novel chimeric degrader against bromodomain-containing (BRD) proteins, inducing the interaction of AhR and BRD proteins and displaying effective anticancer activity that correlated with protein knockdown activity

Novel chimeric degrader against cellular retinoic acid binding proteins (CRABPs), inducing the AhR-dependent degradation of CRABP-1 and CRABP-2 via the ubiquitin-proteasome pathway

Potent furin inhibitor, blocking furin-dependent cell surface processing of anthrax protective antigen-83 in vitro.

Elongation factor P (EF-P) fuction modifier

Novel antimalarial agent

The first selective inhibitor of Histone Deacetylase 2 (HDAC2)

Novel inhibitor of Pak1 activation, anti-cancer ingredient isolated from the Chinese traditional herb Curcuma wenyujin

Non-selective potent dopamine reuptake inhibitor

Non-selective potent dopamine reuptake inhibitor

Potent competitive inhibitor of indoleamine 2,3-dioxygenase (IDO)

Potent ß-amyloid aggregation inhibitor; Antioxidant

Novel antiestrogen, lacking estrogenic and genotoxic actions

Novel potent inhibitor of Staphylococcus aureus sortase A (SrtA)

Novel selective CXCR2 antagonist

Novel potent SIRT1 activator

Novel Sirtuin1 Activator, Down-Regulating Sclerostin and Rescuing Ovariectomy-Induced Bone Loss

Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice

Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri

Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri

Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells

Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv)

Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding

Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons.

Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist

Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK)

Peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR)

Novel Selective TBK1/IKK dual inhibitor with anticancer potency